Company Dianthus Therapeutics, Inc.

Equities

DNTH

US2528281080

Biotechnology & Medical Research

End-of-day quote Nasdaq Other stock markets 2024-09-06			5-day change	1st Jan Change
26.62 ^USD	-4.86%		-3.73%	+155.96%

Aug. 09	Wedbush Adjusts Dianthus Therapeutics' PT to $36 From $38, Keeps Outperform Rating	MT
Aug. 08	Dianthus Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI

Business description: Dianthus Therapeutics, Inc.

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to advancing antibody complement therapeutics to treat severe autoimmune diseases. The Company is dedicated to designing and delivering monoclonal antibodies with improved selectivity and potency. The Company has initiated a Phase 2 trial of DNTH103, a potential active C1s inhibitor, in generalized Myasthenia Gravis and plans to initiate additional Phase 2 trials in other neuromuscular indications, including Multifocal Motor Neuropathy and Chronic Inflammatory Demyelinating Polyneuropathy. Its product candidate, DNTH103, is a clinical-stage, highly potent, highly selective and fully human monoclonal immunoglobulin G4 with picomolar binding affinity that is designed to selectively bind only to the active form of the C1s complement protein. DNTH103 is engineered with YTE half-life extension technology, a specific three amino acid change in the Fc domain, and has a pharmacokinetic (PK) profile.

Number of employees: 53

Sales by Activity: Dianthus Therapeutics, Inc.

Fiscal Period: December	2021	2022	2023
Biotechnology (Startups)	1.48M	6.42M	2.83M

See all business segments

Geographical breakdown of sales: Dianthus Therapeutics, Inc.

Fiscal Period: December	2021	2022	2023
United States	1.48M	6.42M	2.83M

See all geographic segments

Managers: Dianthus Therapeutics, Inc.

Director	Title	Age	Since
Marino Garcia CEO	Chief Executive Officer	57	23-09-10
Ryan Savitz DFI	Director of Finance/CFO	35	23-09-10
Jeffrey Stavenhagen CTO	Chief Tech/Sci/R&D Officer	-	Nov. 28
Sankalp Gokhale CTO	Chief Tech/Sci/R&D Officer	-	23-09-10
Angela Norton CTO	Chief Tech/Sci/R&D Officer	-	23-09-10

See DIANTHUS THERAPEUTICS, INC. governance

Members of the board: Dianthus Therapeutics, Inc.

Manager	Title	Age	Since
Lonnie Moulder CHM	Chairman	66	23-09-10
Tomas Kiselak BRD	Director/Board Member	38	23-09-10
Paula Soteropoulos BRD	Director/Board Member	56	23-09-10
Jonathan Violin BRD	Director/Board Member	48	23-09-10
Alison Lawton BRD	Director/Board Member	63	23-09-10
Anne McGeorge BRD	Director/Board Member	63	23-09-10
Marino Garcia CEO	Chief Executive Officer	57	23-09-10
Lei Meng BRD	Director/Board Member	52	23-09-10

Composition of the Board of Directors

Shareholders: Dianthus Therapeutics, Inc.

Name	Equities	%	Valuation
Fidelity Management & Research Co. LLC 15.00 %	4,402,420	15.00 %	127 M $
Bain Capital Life Sciences LP 10.27 %	3,013,423	10.27 %	87 M $
Avidity Partners Management LP 9.938 %	2,917,231	9.938 %	84 M $
Fairmount Funds Management LLC 9.412 %	2,762,837	9.412 %	80 M $
RA Capital Management LP 7.948 %	2,333,000	7.948 %	67 M $

List of DIANTHUS THERAPEUTICS, INC. shareholders

Company details: Dianthus Therapeutics, Inc.

Dianthus Therapeutics, Inc.

7 Times Square 43rd Floor

10036, New York

http://dianthustx.com

address Dianthus Therapeutics, Inc.(DNTH)

Bio Therapeutic Drugs

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
DIANTHUS THERAPEUTICS, INC.	-4.86%	-3.73%	-	-	818M
REGENERON PHARMACEUTICALS, INC.	-0.74%	-2.78%	+36.80%	+74.69%	124B
VERTEX PHARMACEUTICALS INCORPORATED	-0.07%	-1.03%	+37.23%	+149.66%	122B
ARGENX SE	-2.14%	+4.52%	+0.72%	+74.98%	32.94B
BIONTECH SE	+0.10%	+14.35%	-16.23%	-71.18%	23.9B
BEIGENE, LTD.	+2.27%	+5.01%	+2.63%	-43.83%	20.54B
GENMAB A/S	-0.08%	-0.91%	-29.68%	-33.42%	17.42B
WUXI APPTEC CO., LTD.	-5.38%	-2.87%	-51.06%	-73.52%	15.77B
VAXCYTE, INC.	+0.82%	+5.52%	+129.34%	+344.30%	14.26B
SUMMIT THERAPEUTICS INC.	+20.01%	+82.30%	+1,391.56%	+253.38%	13.87B
Average	+0.99%	+9.41%	+166.81%	+75.01%	38.47B
Weighted average by Cap.	+0.20%	+3.23%	+74.47%	+88.52%